Bring your
RNA to life

With nearly 30 years of RNA-focused expertise, Hongene offers seamless support from raw materials to GMP drug products. Our vertically integrated platform simplifies complex supply chains, reduces risk, and speeds your program to market—all while ensuring quality you can trust.

Vertically integrated CDMO services for RNA therapeutics

From raw materials to GMP drug product: Fewer handoffs, faster timelines, greater confidence.

  • Oligonucleotide CDMO Services

    End-to-end CDMO services for oligonucleotide therapeutics, from early development through cGMP clinical supply and commercial manufacturing.

    Learn More
  • mRNA CDMO Services

    End-to-end CDMO services for mRNA therapeutics, from IVT template preparation through formulation and fill-finish.

    Learn More
  • Custom Synthesis Services

    Custom synthesis of nucleic acid building blocks, monomers, and specialty reagents

    Request a Quote

Raw materials manufacturing at scale with unmatched purity

Explore raw material categories for RNA therapeutics, from synthesis building blocks to enzymes and cap analogs.

Hongene at a Glance

Powering RNA programs with deep expertise, consistent high quality, and capacity built for scale.

  • 28 Years

    RNA-focused expertise

  • ~2,000

    Global Workforce

    ~400 FTEs in R&D

  • 2,000+

    product SKUs

  • 2,000+

    impurity profiles

  • Multi-Ton

    oligo DS capacity

  • 58 tons

    annual phosphoramidite capacity

Advanced Platforms

Integrated supply and specialized technologies to support the development and manufacture of RNA therapeutics.

  • Vertically-integrated Supply Chain

    From building blocks to drug substance and drug product, Hongene’s vertically integrated platform reduces handoffs, improves continuity and supports more efficient program execution.

    1. Building blocks
    2. Drug substance
    3. Drug product
  • Chemoenzymatic Ligation

    HiXPEL™ Chemoenzymatic Ligation Platform

    Support next-generation oligonucleotide therapeutics by improving scalability and manufacturing efficiency for selected applications, including siRNA, dual-target siRNA, ADC, sgRNA, and pegRNA.

  • mRNA Cap Technology

    HiXCap™ Cap Analog Platform

    A new generation of rationally designed 5’ cap structures to enhance mRNA translation efficiency by reducing IFIT1-mediated immune suppression.

Have a program? Talk to our experts now.

Discuss your RNA program, raw material needs and manufacturing requirements with the Hongene team.